Equibles does not estimate personal net worth.
Get an email with a short summary when Pelthos Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get PTHS alertsPelthos Therapeutics Inc. reported in an 8-K filed July 2, 2025 that Sai Rangarao was appointed Chief Commercial Officer, effective July 1, 2025. The proxy statement of Pelthos Therapeutics Inc. reports total compensation of $1,723,407 for Sai Rangarao in fiscal 2025, including a base salary of $200,733. Disclosed compensation is on record for 2 fiscal years. Sai Rangarao has spoken on 3 earnings calls across 1 company, most recently for Pelthos Therapeutics Inc. on November 12, 2026. Pelthos Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Pelthos Therapeutics Inc. includes Christian Kopfli (CEO), Francis Knuettel II (CEO, CFO and Chief Accounting Officer), Scott Plesha (CEO and Board Member) and 7 others.
“In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers of the Company: | **Name of Executive Officer** | **Age** | **Position** | | --- | --- | --- | | Scott Plesha | 61 | Chief Executive Officer, President and Director | | Francis Knuettel II | 59 | Chief Financial Officer (principal financial officer and principal accounting officer) | | Sai Rangarao | 41 | Chief Commercial Officer |”
“I am pleased to provide an update on our Q3-2026 Dalsuzmi performance and our progress to date. Zelsuzmi continues to deliver strong utilization and adoption among HCPs and patients.”
“I'm pleased to provide an update on our Q2 2026 Zelsudmi performance. Our progress to date continues to deliver better-than-expected results in our first full year or four full quarters since launch.”
“I'm pleased to provide an update on our Q1-2026 ZELSUVME performance. Our progress to date continues to deliver better-than-expected results in just our third quarter since launch.”
Proxy statement
Start not stated–present
Last confirmed August 18, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pelthos Therapeutics Inc. (PTHS) | Chief Commercial Officer | $200,733 | $1,723,407 |
| 2024 | Pelthos Therapeutics Inc. (PTHS) | Chief Commercial Officer | — | — |
